




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61M 11/00, 15/00, 16/10 B05B 1/26		A1	(11) International Publication Number: WO 94/03225 (43) International Publication Date: 17 February 1994 (17.02.94)
(21) International Application Number: PCT/US93/07515 (22) International Filing Date: 10 August 1993 (10.08.93)			(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority data: 927,834 10 August 1992 (10.08.92) US			Published <i>With international search report.</i>
(71)(72) Applicants and Inventors: RIGGS, John, H. [US/US]; 201-F Foliage Circle, Cary, NC 27511 (US). NANGUM, Barry, O. [US/US]; 6116 Chowning Court, Raleigh, NC 27612 (US).			
(74) Agent: HULTQUIST, Steven, J.; Intellectual Property/ Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US).			

(54) Title: LOW FLOW RATE NEBULIZER, METHOD AND APPARATUS



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	CN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

LOW FLOW RATE NEBULIZER, METHOD AND APPARATUS .

Description

Field of the Invention

The present invention relates to a low flow rate nebulization method and a low flow rate nebulizer apparatus used in respiratory care and, in particular, to a continuously connected, continuous low gas flow rate liquid nebulizer useful in respiratory care to deliver liquid medications.

Description of the Related Art

Critically ill patients requiring mechanical ventilation are often victims of respiratory distress syndrome, status asthmaticus and pulmonary infections. Treatment of these and other sever respiratory conditions includes medications delivered directly to the lungs of the patient.

Respiratory delivery of medication for these conditions is preferable to oral, intravenous and subcutaneous delivery because it is non-invasive, permits rapid action of medicament, requires a relatively small dosage, is not filtered through the liver of the patient, and produces a low incidence of systemic side effects.

Nebulized or aerosolized solutions are the preferred method of respiratory delivery of medication; when fragmented into small particles, medicants are more efficiently deposited near sites of medicant activity in the lung.

Respiratory medications may be delivered to the lungs of the patient as an aerosol of a liquid or a powder. Clinical aerosols are currently generated by jet or ultrasonic nebulizers, metered dose inhalers (MDI) and dry powdered inhalers.

Liquid nebulizers are well known in the art. Aerosolization of liquid medications is performed by putting a liquid product in a chamber (nebulizer vial)

that has a pressurized flow of gas through it. Utilizing the Bernoulli principle, liquid is drawn through an aspirator tube into the path of a high velocity gas and is fractured into a mist. The mist flows out of the nebulizer by inertial forces.

There are two principal types of nebulizers for the delivery of liquid medication to the lungs: jet nebulizers and ultrasonic nebulizers. In conventional jet nebulizers, compressed gas from a compressor or hospital air line is passed through a narrow constriction known as a jet. This creates an area of low pressure, and liquid medication from a reservoir is drawn up through a feed tube and fragmented into droplets by the airstream. Only the smallest drops leave the nebulizer directly, while the majority impact on baffles and walls and are returned to the reservoir. Consequently, jet nebulization takes several minutes to complete, depending upon the initial volume.

Important disadvantages of nebulizers include low lung deposition related to the use of tidal breathing. A substantial portion of the dose used in a jet nebulizer is retained permanently as a dead or residual volume on baffles and internal walls of the nebulizer chamber and cannot be released. Generally only 2-10% of the dose placed in the nebulizer ever reaches the lung. The consequences are a higher drug dosage and longer administrative time, along with the associated cost and risk of contamination.

Current conventional liquid aerosol drug therapy involves administering a finite quantity (dose) of liquid medication deposited into the nebulizer vial and administered until the vial is empty. In normal practice, the period of delivery of each dose is measured in minutes or fractions of an hour. Depending upon the severity of the illness and the duration of activity of the medication, this process is repeated periodically at variable frequencies.

Such intermittent drug administration has the inherent results of (1) subjecting the patient to "peaks and "valleys" of drug dosage effects, (2) requiring respiratory therapy personnel to periodically service the needs of the patient and nebulizer by measuring doses, disconnecting, filling and reconnecting the nebulizer and periodically monitoring the administration, and (3) disconnecting the patient from an attached ventilator during nebulizer service. Further, medication which is administered as a large volume, such as a surfactant, now requires large

medicant flow volume through the nebulizer requiring frequent servicing and refilling of the nebulizer vial which interferes with ventilator function.

In some cases, a significant proportion of the respiratory flow to the patient is through the nebulizer such as in the operational use of the VISAN nebulizer of Burroughs Wellcome Company. In the delivery of the medicant EXOSURF® surfactant, up to half of the tidal volume flows through the nebulizing ports of the nebulizer to unite with the balance of the respiratory gas delivered directly from the ventilator in a Y-shaped junction in the flow path to the patient downstream from the nebulizer. In such delivery, the nebulizing gas is synchronized with the nebulizer such that nebulizing gas is delivered to the nebulizer only during the ventilatory inhalation cycle.

A nebulizer comprising a vial-like nebulizing chamber which comprises a two-position flow control valve assembly for accessibly draining and refilling the nebulizing chamber is disclosed in U.S. Patent 4,805,609. While the valve assembly provides access for resupplying a medication close while the nebulizing chamber remains in sealed relation with the nebulizer, such resupply is service intensive and limited to volumes containable by the nebulizing chamber.

Recent developments in respiration therapy involve aerosolization and delivery of nebulized mist on a continuous basis over several hours. For example, an entire day's medication dosage is delivered at a constant rate over twenty-four hours, as opposed to conventionally delivering the same dosage as four separate aliquots at six hour intervals. Such delivery eliminates the "peak" and "valleys" effects of the drug, reduces respiratory personnel support time, and also reduces the number of time critical medication/nebulizer interconnections are interrupted, thereby diminishing the potentially dangerous exposures of the patient to the effects of respiratory circuit contamination.

Delivery of medicated mist is both in combination with a ventilator and through masks, mouthpieces, and other voluntary mist inhalation apparatus.

The second type of aerosol generator is a metered dose inhalator (MDI), which delivers a bolus of more concentrated drug aerosols than the solution commonly available for nebulizers. For optimal effect, MDI delivery systems

require proper administration technique, which includes coordinated actuation of aerosol delivery with inhalation, a slow inhalation of 0.5-0.75 liters per second, a deep breath approaching inspiratory capacity inhalation, and at least 4 seconds of breath holding.

Many patients find it difficult to properly administer medication with an MDI, especially during acute exacerbation. An article which appeared in *Eur. J. Respir. Dis.*, 68(5), 332 (1986), entitled "Bronchodilator Affects of a Fenoterol Meter Dose Inhaler and Fenoterol Powder in Asthmatics with Poor Inhaler Technique," described test findings showing that the effectiveness of bronchodilator medication, when delivered with an MDI, is dependent on good MDI technique. The article suggested that delivery of medication in a powdered form is more reliable for patients who do not exercise proper MDI technique.

MDI's can be equipped with devices that automatically couple actuation to inspiratory effort, thus eliminating the need for coordinating hand action with inhalation. Devices such as spacers and holding chambers also decrease partial velocity and reduce the number of large particles. Both of these features reduce oral pharyngeal and large airway deposition with a consequent reduction in systemic absorption. Deposition of aerosols from an MDI with a spacer or holding chamber is similar and perhaps better than the deposition of a properly used MDI alone.

Advantages of the MDI include deposition of 10-15% of the metered dose with consequent short treatment time, low cost and increased convenience. However, MDI's cannot be used by patients requiring mechanical ventilation. Other advantages include the need for patient cooperation, the practical limitations and inconveniences associated with increased dosing requirements due to the typically small dosages administered with an MDI, the limited number of currently available drugs, and the dependence on fluorocarbons of aerosol generation.

Others have recognized the need for new inhalation devices such as modified dry powder inhalers to replace use of MDI's due to environmental concerns related to the use of fluorocarbons. See "Today's Treatment of Airway Obstruction...and Tomorrow's?" Flenley, D.C., *Respiration*, 55 Suppl. 2, 4 (1989).

The third type of aerosol generator is a dry powder inhaler. Dry powdered inhalation devices currently in use are the Spinhaler, the Rotahaler, the Turbuhaler and the disc inhaler. Dry powdered inhalers are breath actuated and usually require a higher inspiratory flow rate than that required for an MDI or a nebulizer. Flow rates of 1-2 liters per second are usually considered optimal, although flow rates as low as 0.5 liters per second may be effective for some dry powdered inhalers.

Advantages of dry powdered inhalers include relative ease of administration and the fact that they do not require fluorocarbon propellants. When a dry powdered inhaler is used properly, deposition appears to be similar to that of a properly used MDI.

However, powdered inhalers are limited by the dose they can provide and by the number of drugs currently available. Only terbutaline, salbutamol, dexamethasone and chromolyn sodium are available in powder form.

All conventional powder inhaler delivery systems utilize single dose capsules except the Turbuhaler for administration of terbutaline. While several devices have been developed which permit preloading of several single dose capsules, neither these devices nor the Turbuhaler have eliminated the other disadvantages of conventional powdered inhalers. See "A New Inhalation System for Bronchodilation. Study of the Acceptance of the Ingelheim M Inhaler in Chronic Obstructive Respiratory Tract Disease." Mutterlein, B. Schmidt, B., Fleisher, W., and Freund, D., *Fortschr. Med.*, April 15, 108(11), 225 (1990); "In Vivo Evaluation of the New Multiple Dose Powder Inhaler and the Rotahaler Using the Gama Scintigraphy," Vidaren, M., Paronen, P., Vidaren, P. Vainir, P., and Nuutinen, J., *Acta. Pharm. Nord.*, 2(1), 3 (1990); "Clinical Use of Dry Powder Systems," Crompton, G. K., *Eur. J. Respir. Dis. Suppl.*, 122, 96 (1962).

Other disadvantages of dry powdered inhalers include the following: a) they are usually not particle size-selective and thus heavy oral pharyngeal deposition may occur; b) high humidity environments may cause clumping of the particles; and c) dry powdered inhalers cannot be used in ventilatory circuits.

Currently available devices for delivery of powdered medications to respiratory therapy do not employ nebulization technology.

The use of compressed air powered jet mills as a power generator or inhalation experiments is disclosed in "Use of a Jet Mill for Disbursing Dry Powder for Inhalation Studies," Cheng, Y.S., Marshall, T.C., Henderson, R.R., and Newton, G. J., *Am. Ind. Hyg. Assoc. J.*, 46(8), 449 (1985). The jet mill consisted of an elongated channel, one material delivery jet, and two high speed air jets. Powder fed into the channel was disbursed by turbulence and centrifugal forces. The powder used in the inhalation experiments consisted of dye materials to be tested for toxicity. A flow rate of 400 liters per minute was maintained. The article does not address nebulization of powdered medication for purposes of respiratory therapy.

U.S. Patent 4,232,002 discloses procedures for administering antihistamines. Methods disclosed include inhalation by a patient of mist, nebulized spray, or a cloud of fine solid particles. Products for delivery of medication include pressurized canister inhalers, portable dry powder insuffilators using capsules, and nebulizer. The only dry powder delivery system described is a dry powder inhaler using capsules of dry powder in single dose units. The delivery method described involves puncturing a capsule of dry powder medication which is disbursed by means of a turbomixer to be inhaled through a mouth piece. This patent does not address continuous flow or continuous delivery of inhalable medication. It does not enablingly teach or address jet nebulization of powdered solid medications, and does not teach a nebulizer vial which connects to a nebulizer to provide a device for introducing continuous flow.

U.S. Patent 3,669,113 discloses a method and device for dispensing powdered medication from a perforated container by rotating the container by pneumatic means and causing the axis of rotation to the container to precess and describe a path of precession which is contained within a generally conical surface of a precession. The mechanisms described are based on varying shaft and bearing configurations. The method of this patent is said to be especially well suited to delivery of particles less than 80 microns in diameter. The patent does not address jet nebulization, continuous flow or continuous nebulization.

Recent developments in respiration therapy involve aerosolization and delivery of nebulized liquids on a continuous basis over several hours. Such delivery stabilizes the effects of the medication over time, reduces respiratory personnel support time, and reduces the changes of respiratory circuit contamination.

In our prior co-pending U.S. Patent Application No. 07/729,518, filed July 12, 1991, a liquid nebulizer system is disclosed comprising a nebulizer attachable nebulizer vial, a large supply vessel, and a fluid delivery system, to be used with a conventional liquid nebulizer. The liquid nebulizer system provides for continuous delivery of liquid medication from a large supply vessel into the nebulizer vial which is attached to a conventional nebulizing apparatus, permitting continuous delivery of nebulized liquid medication. The disclosure of such prior copending application is hereby incorporated herein by reference.

In conventional, commercially available liquid nebulizer systems, a carrier gas flow rate in the range of from about 6 to about 8 liters per minute is used. Such flow rate range is necessary for conventional nebulizer devices to operate with suitable efficiency, but such relatively large flow rates also lead to substantial loss and wastage of the nebulized drug, due primarily to the fact that the flow rates in such range exceed the patient uptake rate on a continuous basis.

It is possible to reduce carrier gas flow rate below such 6-8 liter per minute range, but at such lower flow rates, nebulization efficiency becomes disproportionately poorer as the flow rate is reduced to levels as low as 4-5 liters per minute, with the result that a carrier gas flow rate of 4 liters per minute is considered a conventional "low flow" regime defining the limits of operability of commercially available liquid nebulizer devices.

Further, even at such "low flow" conditions on the order of 4-5 liters per minute, the tidal volume respiratory gas is substantially larger than lung capacity for neonatal patients and others with reduced lung capacity such as patients who possess only one lung. At low flow rates, on the order of 4-5 liters per minute, the nebulization efficiency becomes unsuitable since the gas flow rate is not adequate to produce a usefully fine particle size distribution of the medicant.

Accordingly, where low flow delivery of medicant materials is required, the only practical device is an ultrasonic nozzle. However, ultrasonic nozzles suffer the deficiencies that they are costly, tend to denature a variety of otherwise useful drugs which in denatured form are non-efficacious, and ultrasonic nozzles tend to have a short operating life, due to nozzle wear and degradation.

It would therefore be highly desirable to provide a liquid nebulizer device which is usefully employed to delivery medicant materials in a carrier gas flow stream at a flow rate substantially below the range of 4-5 liters per minute, which is the practical lower limit with conventional nebulizer apparatus.

Accordingly, it is an object of the present invention to provide such a liquid nebulizer system capable of operating at carrier gas flow rates substantially below the 4-5 liter per minute practical lower limit of currently available commercial nebulizer devices.

It is another object of the present invention to provide a nebulization system of such type which may be used for delivery of liquid as well as solid medicaments.

It is a further object of the present invention to provide a method and apparatus for continuous respiratory delivery by low flow rate gas nebulization of liquid medicaments.

It is still another object of the present invention to provide a method and apparatus for respiratory delivery of low gas flow nebulization of liquid medication which may be used in ventilatory circuits.

It is yet another object of the invention to provide a method and apparatus which overcome the disadvantages associated with currently available respiratory medicant delivery systems.

These and other objects and advantages of the present invention will be more fully apparent from the ensuing disclosure and appended claims.

SUMMARY OF THE INVENTION

In a broad apparatus aspect, the present invention relates to a nebulizer device, comprising:

(a) a housing defining an interior volume therewithin, including a reservoir portion for holding medicament therein for entrainment into a carrier gas to form a delivery gas mixture comprising nebulized medicament and carrier gas;

(b) a discharge port connected to the housing in flow communication with the interior volume therewithin, for discharging the delivery gas mixture from the housing;

(c) a jet passage member having (i) an inlet portion for introduction of carrier gas thereinto and (ii) a nozzle portion positioned in the interior volume of the housing for discharging carrier gas in jet form in the interior volume, for entrainment of medicament from the reservoir portion of the housing in the carrier gas jet, said nozzle portion comprising a nozzle orifice accommodating carrier gas flow therethrough, wherein the nozzle orifice has an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch.

In the above-described apparatus, the nozzle orifice preferably is in the range of from about 0.007 inch to about 0.018 inch, more preferably from about 0.008 inch to about 0.015 inch, and most preferably from about 0.010 inch to about 0.012 inch.

The nebulizer device in one embodiment particularly suited for nebulization of liquid medicants may further comprising means disposed in the interior volume of the housing for delivering liquid from the reservoir portion of the housing to a discharge locus of the nozzle orifice of the jet passage member, whereby delivered liquid is entrained in carrier gas flowed through the jet passage member when the reservoir portion contains liquid. In a specific embodiment, such means may comprise a nebulization structure mounted in the interior volume of the housing, including: an expansion chamber in flow-receiving communication with the nozzle portion of the jet passage member, such expansion chamber having an orifice therein, in alignment with the orifice of the jet passage member; an impingement baffle presenting an impingement surface in alignment with the orifices of the jet passage member and the expansion chamber; and means for

aspiratingly delivering liquid from the reservoir portion of the housing when liquid is contained in the reservoir and carrier gas is flowed in sequence through the orifices of the jet passage member and the expansion chamber at sufficient volumetric flow rate. In such embodiment, the orifice in the expansion chamber has an equivalent orifice diameter in the range of from about 0.025 inch to about 0.060 inch, and preferably from about 0.030 inch to about 0.050 inch.

The nebulizer devise of the invention may further comprise pressurized carrier gas supply means coupled in gas-supplying relationship with the inlet portion of the jet passage member, and/or a breathing circuit coupled with the discharge port for receiving delivery gas mixture and conveying same to a patient interconnected with the breathing circuit.

In one method aspect, the present invention relates to a method of delivering a nebulized medicant to a patient, comprising:

(a) providing a nebulizer apparatus including a breathing circuit coupled to the patient and including a nebulizer device (i) containing the medicant, and (ii) constructed and arranged for producing a pulmonarily effective nebulized medicant in a carrier gas passed through the nebulizer device at a carrier gas flow rate in the range of from about 0.5 to about 3.25 liters per minute;

(b) flowing the carrier gas through the nebulizer device at a flow rate in the range of from about 0.5 to about 3.25 liters per minute, to disperse the medicant into the carrier gas and form said pulmonarily effective nebulized medicant in the carrier gas, as a medicant/carrier gas mixture; and

(c) passing the medicant/carrier gas mixture through the breathing circuit to a pulmonary situs of the patient.

In another method aspect, the present invention relates to a method of delivering a nebulized medicant to a patient, comprising:

(i) providing a nebulizer apparatus including a breathing circuit coupled to the patient and including a nebulizer device, wherein the nebulizer device comprises:

(a) a housing defining an interior volume therewithin, including a reservoir portion for holding medicament therein for entrainment into a carrier gas to form a delivery gas mixture comprising nebulized medicament and carrier gas;

(b) a discharge port connected to the housing in flow communication with the interior volume therewithin, for discharging the delivery gas mixture from the housing;

(c) a jet passage member having (i) an inlet portion for introduction of carrier gas thereto and (ii) a nozzle portion positioned in the interior volume of the housing for discharging carrier gas in jet form in the interior volume, for entrainment of medicament from the reservoir portion of the housing in the carrier gas jet, such nozzle portion comprising a nozzle orifice accommodating carrier gas flow therethrough, wherein the nozzle orifice has an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch;

(II) disposing a medicant in the reservoir portion of the housing;

(III) flowing the carrier gas through the jet passage member of the nebulizer device at a flow rate in the range of from about 0.5 to about 3.25 liters per minute, to disperse the medicant into the carrier gas and form a pulmonarily effective nebulized medicant in the carrier gas, as a medicant/carrier gas mixture; and

(IV) passing the medicant/carrier gas mixture through the breathing circuit to a pulmonary situs of the patient.

In the practice of the method of the present invention, the carrier gas flow rate preferably is in the range of from about 1.0 to about 3.0 liters per minute, and most preferably is in the range of from about 2.2 to about 2.8 liters per minute.

The medicant which is administered to the patient in the practice of the nebulization technology of the present invention may for example comprise a material selected from the group consisting of lung surfactants or precursors thereof, terbutaline, salbutamol, dexamethasone, chromolyn sodium, pentamidine, and bioactive substances encapsulated in a pulmonarily degradable encapsulant medium.

As used herein, the term "equivalent orifice diameter" refers to the diameter of an orifice having a circular opening which is equivalent in cross-sectional open area (i.e., the open area of the orifice opening perpendicular to the direction of the flow of carrier gas therethrough) to the cross-sectional open area of the actual orifice in the nebulization system of the present invention. This terminology defines the dimensional character of the orifice regardless of the actual shape of the orifice opening, and thus the invention contemplates the employment of orifice openings which are of circular or generally circular opening shape, as well as orifice openings which are of non-circular or irregular opening shape. Of course, when the orifice opening is of circular shape, the equivalent orifice diameter of such opening is identical to its actual diameter. Preferably, the orifice opening is of circular shape, or at least generally circular shape, although as mentioned, other non-circular shapes, e.g., square, ovoid, rectangular, star-shape, cruciform, etc. shapes, may advantageously be employed within the broad practice of the present invention.

As used herein, the terms "medicant" and "medicament" are intended to be broadly construed to include any substances, formulations, compositions, compounds, materials, etc. which are physiologically beneficial.

As used herein, the term "pulmonarily effective" means physiologically beneficial in application to a patient at a pulmonary situs, viz., the lungs and associated inspiratory and expiratory passages and body structures.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of a patient receiving respiratory support and medication via a continuous flow liquid nebulizing device interposed between an endotracheal tube and a ventilator.

Figure 2 is an exploded perspective view of a nebulizer and a continuous flow supporting system comprising a large medication storage vessel, a rate

controllable pump, an influent port accessible nebulizer vial separated from the nebulizer device upper portion, and influent flow regulating and supply devices.

Figure 3 is an elevational cross-section of the nebulizer device of Figure 2.

Figure 4 is an elevational cross-section of a low flow rate jet structure of a type such as may be alternatively employed in the nebulizer device of Figure 2.

Figure 5 is a schematic representation of a patient receiving respiratory support and medication via a powder nebulizing device interposed between an endotracheal tube and a ventilator.

Figure 6 is an elevational cross-section of the powder nebulizer device of Figure 5.

DETAILED DESCRIPTION OF THE INVENTION, AND PREFERRED EMBODIMENTS THEREOF

In this description, the term "proximal" is used to indicate the segment of the device normally closest to the patient when it is being used. The term "distal" refers to the other end. Herein the term nebulizing device is defined to be a nebulizing unit or instrument used to aerosolize fluid or disperse particulate solid material, e.g., powder, for delivery to a patient. The term nebulizer vial is sometimes used herein to denote the portion of a nebulizing device which comprises a container providing a reservoir for fluid or particulate solid material to be nebulized. The term nebulizer is sometimes used herein to denote the non-nebulizer-vial portion of the nebulizing device which comprises at least a portion of the nebulizing mechanism. Reference is now made to the embodiments illustrated in Figures 1-3 wherein like numerals are used to designate like parts throughout.

As seen in Figure 1, a patient 30, undergoing respiratory therapy, is fitted with an endotracheal tube 24. The proximal trunk end 18 of a "Y"-shaped connector 32 is insertably connected to a distal end 25 of endotracheal tube 24. One bifurcated distal end 34 of "Y"-shaped connector 32, is insertably connected

to a proximal port 22 of a nebulizer 20 which is part of a nebulizing device 48. Nebulizer 20 is disposed between distal end 34 of "Y"-shaped connector 32 and a proximal end 14 of a respiratory gas delivery tube 12. Thereat a distal part 38 of nebulizer 20 is insertably connected to gas delivery tube 12. Gas delivery tube 12 provides the distal portion of inhalation respiratory pathway 26 and connects to the output inhalation gas of a ventilator 10. Ventilator 10 therapy supplies periodic, breath-sustaining pulses of pressurized gas through tube 12, nebulizer device 48, and "Y"-shaped connector 32 into endotracheal tube 24 and to patient 30.

The other distal end 36 of "Y"-shaped connector 32 comprises a proximal portion of an exhalation respiratory pathway 28 which further comprises tube 16 which returns exhalation flow to ventilator 10. Many different ventilators are known and available in the art. Generally, ventilators which are conventionally used with nebulizers may be used with the invention.

Nebulizer 20 receives a supply of nebulizing gas from a flow meter 40 along a fluid pathway 26' which passes through a tube 42 interposed and connected between flow meter 40 and a top nebulizer inflow connecting tube 44'. Flow meter 40 receives a pressurized gas from a gas source 44 through a connecting tube 42'. Gas pressure from gas source 44 is sufficient to provide the volumetric flow for which flow meter 40 is preset. Gas source 44 may comprise pressurized oxygen or other breathable gas from a hospital pressurized O₂ delivery system, from a tank of compressed oxygen, a blender, directly from ventilator 10, or from other sources of pressurized gases conventionally used in respiratory therapy. Flow meters are well known and widely used in the art. Such flow meters may comprise macro and vernier adjustable controls for very accurate and precise gas flow settings. Although O₂ is preferred for some selected medicants, source 44 may supply oxygen blended with other gases.

Nebulizing device 48 comprises nebulizer 20 which functions in combination with an attached nebulizer vial 50. Nebulizing device 48 nebulizes or aerosolizes fluids contained in reservoir 72 in nebulizer vial 50, thereby producing a mist which is carried to patient 30 by influent flow of gas from ventilator 10 through pathway 26 and by nebulizing gas received from gas source 44. Delivery

of nebulized fluid to patient 30 is therefore dependent upon the availability of fluid resident in the reservoir 72 at any given moment.

In a currently preferred embodiment shown in Figures 1 and 2, a continuous flow system 106 provides substantially continuous delivery of fluid to nebulizer vial 50 to maintain the volume of liquid at an adequate and essentially unchanging level in reservoir 72. Continuous flow system 106 comprises (i) nebulizer vial 50, (ii) at least one influent access port 50 to nebulizer vial 50, (iii) connecting tubing 54 interposed between a pump 60 and connected at influent access port 52, (iv) the pump 60, (v) additional tubing 58 providing a medicant pathway 56' interposed between and connected to pump 60 and a large medicant supply vessel 70, and (vi) the large medicant supply vessel 70. As continuous flow system 106 maintains a constant volume of liquid in nebulizer vial 50, continuation upon the initial contents of reservoir 72 at the time nebulizer vial 50 is joined to nebulizer 20, but upon the larger volume available in large medicant supply vessel 70. Such supply vessels may be IV bags, bottles or other nebulizing medication and reagent containing vessels from which therapeutic liquids are drawn.

As seen in Figure 2, nebulizing device 48 comprises nebulizer vial 50 which releasably and sealably attaches to nebulizer 20. Such attachment may be by a male threaded member 62 of nebulizer vial 50 insertably joined into a female threaded member 64 of nebulizer 20. When nebulizer 20 is so disposed and connected to nebulizer vial 50, an end 68 of an aspirator tube 66 is disposed below the surface of a reservoir 72 in the bottom of nebulizer vial 50 as best seen in Figure 3.

Nebulizer 20 may be a general construction similar to commercially available nebulizer devices generally used for administration of aerosolized fluids but featuring a jet passage member having (i) an inlet portion for introduction of carrier gas thereinto and (ii) a nozzle portion positioned in the interior volume of the nebulizer housing for discharging carrier gas in jet form in the interior volume, for entrainment of medicament from the reservoir portion of the housing in the carrier gas jet, with the nozzle portion comprising a nozzle orifice accommodating carrier gas flow therethrough, wherein the nozzle orifice has an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch, preferably

from about 0.007 inch to about 0.018 inch, more preferably from about 0.008 inch to about 0.015 inch, and most preferably from about 0.010 inch to about 0.012 inch. Nebulizer vial 50 may suitably comprise a container made to releasably but sealably attach to commercially available nebulizer 20 and, in combination with a gravitational or mechanical pump and a large supply vessel provide a continuously filled reservoir 72 from which medicants are aspirated via aspirator tube 66 into nebulizer 20 and aerosolized. Alternatively the nebulizer vial may be of a conventional type, unconnected to any external liquid supply vessel, for delivery of a unitary dose of medicant from the reservoir portion 72 of the nebulizer housing.

Figure 3 provides a sectional view of nebulizing device 48, comprising nebulizer 20 threadably interconnected to nebulizer vial 50. The following description of nebulizer 20 is provided for a general understanding of the interaction between nebulizer 20 and nebulizer vial 50.

Nebulizer 20, as seen in Figure 3, comprises a housing 262 which comprises a top nebulizer inflow connecting tube 44', a jet passage member 260, with nozzle orifice 203 in the lower nozzle portion thereof, a baffle assembly 268, and aspirator tube 66. Baffle assembly 268 further comprises an aspirator tube connecting orifice 274, a liquid effluent orifice 276, and an impingement baffle 272 in the form of a baffle plate presenting an impingement surface to gas exiting nozzle orifice 203 and liquid entrained in the gas from liquid effluent orifice 276. Pressurized gas which provides the nebulizing high velocity stream for nebulization is provided through top nebulizer inflow connecting tube 44'. The high velocity stream is produced by jet passage member 260 in the direction of impingement baffle 272. As the high velocity stream passes by liquid effluent orifice 276 a resulting below ambient pressure at orifice 276 which is carried by the high velocity carrier gas stream to impact against the impingement surface of impingement baffle 272 to thereby produce a mist.

Housing 262 further comprises a pair of baffles 264 and 266 which lie in inhalation pathway 26 and shield the space where nebulization occurs. A hollow frustoconical baffle 278 is disposed in the medial space between inhalation pathway 26 and the extension of baffles 264 and 266 to limit air flow into nebulizer vial 50 and aid in entraining mist into inhalation pathway 26. While this

description of an illustrative nebulizer embodiment is for a single connecting tube 44', nozzle 260 and associated parts, the number of inflow connecting tubes, nozzles, and associated nebulizer parts may vary in the nebulizer as is well known in the art.

Nebulizer vial 50 is suitably made from synthetic resinous material and preferably is transparent for easy monitoring by a respiratory technician or other patient attendant. The materials of construction of nebulizer vials are well known in the art. They are usually of chemically-inert thermoplastic such as polyolefins or polyvinyl chlorides. Their selection and fabrication are well within the skill of the art.

As seen in Figures 2 and 3, nebulizer vial 50 comprises a port 52 and a therethrough inserted feedthrough 74. Also as seen in combination in Figures 2 and 3, port 52 may be located at different sites in nebulizer vial 50 as required to meet tubing placement and other physical fluid delivery restrictions. As seen in Figure 2, tube 54 is engaged about feedthrough 74 to be reliably but snugly affixed thereat in pressure-sealed relation. Feedthrough 74 comprises a through hole 280, as seen in Figure 3, through which fluid received under pressure from pump 60 flows into nebulizer vial 50. The bottom of nebulizer vial 50 comprises an inverted conically shaped part 76. Apex 78 of inverted conically shaped part 76 provides a low point for fluid contained in reservoir 72 where aspirating tube 66 end 68 is normally disposed when nebulizer 20 is affixed to nebulizer vial 50. A plurality of legs 80 provide a level support when nebulizer vial 50 is disposed on a horizontal surface to maintain fluid at the bottom of inverted conically shaped part 76.

Referring again to Figure 2, large supply vessel 70, seen to be in the form of a plastic container bag, is disposed on a hook 72', such as an IV bag is hung. Tube 58 provides the fluid pathway to pump 60. Pump 60 comprises rate control dial 282 and flow rate display 284 which provide for manual flow rate adjustment. Thereby, the flow rate of pump 60 is set to provide a rate flow of liquid into nebulizer vial 50 which is substantially equal to the rate of loss of liquid from the reservoir 72 through aerosolization. Such a flow rate for pump 60 is derived from a nomogram which comprises the variables of gas flow through flow meter 40 and through ventilator 10. A different nomogram is generated for each combination of

nebulizer 20, flow meter 40, and ventilator 10. Derivation of such nomograms is well within the skill of the art. As disclosed above, pump 60 is a variable flow controlling pump which provides and maintains an accurate and precise flow rate. Pump 60 may be a syringe infusion pump, model number 2001, available from Medfusion, a Medox, Inc. Company, 3450 River Green Court, Duluth, GA 30136.

Figure 4 is a cross-sectional elevation view of a nebulization structure 300 which is mountable in the interior volume of a nebulizer housing, as for example a nebulizer housing of the type illustratively shown and described with respect to Figures 1-3 hereof.

Nebulization structure 300 includes a jet passage member 302 having an inlet portion 304 for introduction of carrier gas thereinto, such carrier gas being introduced from suitable conduit or flow circuit means (not shown) to effect flow of carrier gas into the inlet portion 304 of jet passage member 302 in the direction indicated by arrow A in Figure 4.

Jet passage member 302 further includes a nozzle portion 306, which is positioned in the interior volume of the nebulizer housing, for discharging carrier gas in jet form in the interior volume, through nozzle orifice 308. The nozzle orifice has an equivalent orifice diameter in the range of from about 0.05 inch to about 0.020 inch, and preferably is at least generally circular in cross-sectional shape, transverse to the flow direction indicated by arrow A.

By this arrangement, carrier gas passing through the jet passage member 302 flows through the nozzle orifice 308 in the direction indicated by arrow B, with the carrier gas flow rate suitably being on the order of from about 1.75 to about 3.25 liters per minute.

In this embodiment of Figure 4, the nebulization structure 300 further comprises an expansion chamber 310 in flow-receiving communication with the nozzle portion 306 of the jet passage member. The expansion 310 defines an expansion volume 312 therewithin, and the expansion chamber includes an orifice 314 through which the carrier gas is flowed in the direction indicated by arrow C subsequent to entrainment in such carrier gas of liquid to be nebulized, which enters the expansion volume 312 in the direction indicated by arrow D, from

extension tube 316 of the expansion chamber. Expansion tube 316 has a lower open end 318 as shown, and the tube is journaled or otherwise secured in closed flow relationship to aspiration tube 320 having an interior flow passage 322 and a lower open end 324 into which liquid is aspiratingly drawn in the direction indicated by arrow E.

Secured to the aspiration tube 320, as shown, by means of arm 326 is an impingement member 328 presenting an impingement surface on its upper portion onto which the delivery mixture comprising carrier gas and entrained liquid is impinged, for dispersion in the directions indicated by arrows F in Figure 4.

The impingement member 328 may, as shown, feature a convex impingement surface, whereby dispersion in a wide variety of directions in the interior volume, is achieved.

In use, the nebulization structure 300 is disposed so that the lower open end 324 of aspiration tube 320 is disposed in a pool or body of liquid medicant in the lower reservoir portion of the nebulizer housing. The flow of carrier gas in the direction indicated by sequential arrows A, B, and C causes a reduced gas pressure in the expansion chamber 312 which effects aspiration of liquid through aspiration tube 320 and extension tube 316 to the locus of the expansion chamber 310 interior volume 312 in proximity to nozzle orifice 308. By this arrangement, a highly efficient dispersion of liquid into the gas is achieved, and the droplet size distribution is extremely favorable for highly efficient nebulization, due to the fineness of the mist liquid particles thereby obtained.

Nozzle orifice 308 may suitably have an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch, preferably in the range of from about 0.007 to about 0.018 inch, more preferably from about 0.008 inch to about 0.015 inch, and most preferably from about 0.010 inch to about 0.012 inch.

At equivalent orifice diameter values below about 0.005 inch, the orifice becomes disproportionately more difficult to reliably manufacture and fabricate. Above about 0.020 inch, the velocity of carrier gas flow achievable by the jet passage member becomes unsuitably low to accommodate the low gas flow rate nebulization conditions desired in the practice of the invention. The further

preferred, more preferred, and most preferred ranges represent further balances of these corresponding considerations associated with the end points of the broad range of equivalent orifice diameter values.

Similar considerations dictate the range of permissible sizes potentially employable for the expansion chamber orifice 314, which suitably has an equivalent orifice diameter in the range of from about 0.025 inch to about 0.060 inch, and more preferably from about 0.30 inch to about 0.050 inch.

Correspondingly operational considerations govern the gas flow rate past through the jet passage member of the nebulizer device. In accordance with the low flow rate nebulization method of the present invention, the carrier gas flow rate through the jet passage member is advantageously in the range of from about 0.5 to about 3.25 liters per minute, to disperse the medicant into the carrier gas and form a pulmonarily effective nebulized medicant in the carrier gas, as a medicant/carrier gas mixture. At flow rate values below about 0.5 liters per minute, the volumetric flow rate of carrier gas tends to become insufficient to achieve good dispersion of the medicant in the flowing gas stream. At volumetric flow rate values above about 3.25 liters per minute, the small-size orifice dimensions employed in the practice of the invention tend to produce a back pressure which renders it disproportionately more difficult to achieve a reliable coupling and seal between the inlet portion of the jet passage member and the associated carrier gas flow means. Preferably, the volumetric carrier gas flow rate is in the range of from about 1.0 to about 3.0 liters per minute, and most preferably is in the range of from about 2.2 to about 2.8 liters per minute, based on corresponding considerations, as regards the end point values of the preferred and most preferred ranges, corresponding to the reasons set out above in the respect of the end points of the broad volumetric flow rate range of from about 0.5 to about 3.25 liters per minute. The nebulizer device and nebulization method of the present invention are usefully employed with any of a wide variety of nebulizable materials, including liquid and solid medicants, liquid medicants being advantageously practiced with liquid nebulizer devices in accordance with the present invention, as illustratively embodied in the device shown and described with reference to Figures 1-3 hereof, and the nebulization structure alternatively described in connection with Figure 4 hereof; particulate solid, e.g., powdered, medicants may usefully be administered with powder nebulizer means as more

fully shown and described in our prior copending U.S. patent application number 07/846,784 filed March 4, 1992, the disclosure of which hereby is incorporated herein by reference. An illustratively powder nebulizer potentially useful in the broad practice of the present invention is illustratively described hereinafter with reference to Figures 5 and 6 herein.

Illustrative of medicants which may be administered utilizing the nebulization technology of the present invention are materials such as lung surfactants or precursors thereof (precursors being materials or substances which are converted in situ in the pulmonary locus to surfactant material), terbutaline, salbutamol, dexamethasone, chromolyn sodium and pentamidine, and bioactive substances encapsulated in a pulmonarily degradable encapsulant medium (i.e., a medium in which the bioactive substances encapsulated and which is degradable in the pulmonary locus to release the bioactive substance). The liquid nebulizer apparatus in accordance with the present invention are particularly usefully employed for administration of lung surfactants, such as NEOSURF® (Burroughs Wellcome Company, Research Triangle Park, NC) and pentamidine, which is usefully employed in the treatment of pneumocystis infections accompanying HIV infection, and development of ARC and AIDS.

In application to particulate solids nebulization, the present invention contemplates a method of forming a solid particle dispersion with the use of a carrier gas at the low volumetric flow rate values discussed hereinabove, and with a suitably configured nebulizer apparatus, featuring a jet passage member having the dimensional characteristics described hereinabove.

In the practice of nebulizing particulate solid medicants in the practice of the present invention, the nebulizer housing includes a reservoir portion for the particulate solid medicant, which preferably is general conical-shaped or funicular in shape, for containing the particulate solid to be dispersed. A jet of carrier gas is directed downwardly through the jet passage member to the lower extremity of such generally conical-shape or funicular shaped receptacle to entrain particles of the particulate solid in the carrier, to form a solids dispersion in the carrier gas which then is discharged from the nebulizer device to suitable breathing circuitry means.

In a preferred particulate solid medicant nebulization system, the gas stream directed at the particulate solid is passed through the nozzle orifice of the jet passage member, then expanded and passed through a second orifice of the expansion chamber, with an entrainment structure channeling gas from the receptacle to the jet structure, to increase total gas flow and assist in the production of a gas jet flow stream of desired velocity and pressure characteristics. The entrainment structure may comprise a chamber defining a plenum, with an entrainment port communicating gas flow relationship with the interior volume of the housing, and with an outlet port communicating with the second orifice to cooperatively form a jet structure therewith, as described in the aforementioned prior copending application number 07/846,784.

Referring now to the solids nebulization system shown in Figure 5, a patient 430, undergoing respiratory therapy, is fitted with an endotracheal tube 424. The proximal trunk end 418 of a "Y"-shaped connector 432 is insertably connected to a distal end 425 of endotracheal tube 424. Nebulizing device 448 is connected to arm 434 of "Y"-shaped connector 423 via tube 422 which is interposed and connected between exit port 421 of nebulizer device 48 and arm 34 of the "Y"-shaped connector 432 at port 433. A distal end 435 of arm 434 is insertably connected to a proximal end 14 of gas delivery tube 412. Gas delivery tube 412 provides the distal portion of inhalation respiratory pathway 426 and connects to the output inhalation gas of a ventilator 410. Ventilator 410 therapy supplies periodic, breath-sustaining pulses of pressurized gas through tube 412 and through arm 34 of "Y"-shaped connector 432 into endotracheal tube 424 and to patient 430.

The other distal end 36 of "Y"-shaped connector 432 comprises a proximal portion of an exhalation respiratory pathway 428 which further comprises tube 416 which returns exhalation flow to ventilator 410. Many different ventilators are known and available in the art. Generally, ventilators which are conventionally used with nebulizers may be used with the present invention.

Nebulizer device 448 receives a supply of nebulizing gas from a flow meter 40 along a fluid pathway 426' which passes through a tube 42 interposed and connected between flow meter 440 and a top nebulizer inflow connecting tube 444'. Flow meter 440 receives a pressurized gas from a gas source 444 through

a connecting tube 442'. Gas pressure from gas source 444 is sufficient to provide the volumetric flow for which flow meter 440 is preset. Gas source 444 may comprise pressurized oxygen or other breathable gas from the hospital pressurized oxygen delivery system, from a tank of compressed oxygen, a blender, directly from ventilator 410 or from other sources of pressurized gases used in respiratory therapy. Flow meters are well known and widely used in the art. Such flow meters may comprise macro and vernier adjustable controls for very accurate and precise gas flow setting. Although oxygen is preferred for some selected medicants, source 444 may supply oxygen blended with other gases.

Nebulizing device 448 comprises nebulizer upper portion 420 and a nebulizer receptacle 450. Nebulizing device 448 nebulizes or aerosolizes powdered medication contained in nebulizer receptacle 450 therapy producing a mist (particulate solids-in-gas dispersion) which is carried to patient 430 by influent flow of gas from ventilator 410 through pathway 426' and by nebulizing gas received from gas source 444.

The nebulizing device 448 comprises nebulizer receptacle 450 which is attached to nebulizer upper portion 420. In a specific embodiment, the top of the nebulizer receptacle 450 is 1.5 inches in diameter, the bottom is 0.25 inches in diameter, and the nebulizer receptacle 450 measures 1.5 inches from top to bottom. As shown in Figure 6, an end 468 of nozzle 466 is disposed above the surface of reservoir 472 in the bottom of the nebulizer receptacle 450.

While specific dimensions and tolerances are illustratively set forth herein in respect of the preferred embodiments of the invention, it will be appreciated that the specific size, design, dimensions, and tolerances, may be varied widely within the broad scope of the present invention, with the choice of a specific set of such design parameters being dependent on the particular end use application contemplated in a given instance. The present invention may be embodied in the various embodiments illustrated in our prior co-pending U.S. Patent Application No. 07/729,518, filed July 12, 1991, which is hereby incorporated herein by reference.

Figure 4 provides a sectional view of nebulizing device 448 of Figure 5, comprising nebulizer upper portion 420 and nebulizer receptacle 450.

The nebulizer upper portion 420, as seen in Figure 6, comprises a housing 362 which includes a nebulizer inflow connector tube 444', a first nozzle 360, and a second nozzle 466. Pressurized gas is provided through nebulizer inflow connecting tube 444'. The high velocity stream of gas for nebulization is produced by nozzle 360 and nozzle 466. The pressurized gas is discharged from the first nozzle 466. The pressurized gas is discharged from the first nozzle 360 into the receiving volume 465 of the second nozzle 466, thereby undergoing expansion, following which the gas is discharged into entrainment assembly 467. As the high velocity gas stream passes through entrainment assembly 467, a resulting below ambient pressure within entrainment assembly 467, creates a sufficient pressure differential between entrainment port 469 and nebulizer receptacle 450 to draw gas from nebulizer receptacle 450 through entrainment port 469 and into entrainment assembly 467 where the entrained gas is added to the high velocity gas stream being directed toward reservoir 472. The resultingly augmented gas stream exits entrainment assembly 467 through outlet port 470. The high velocity gas stream thus discharged from jet structure 471 engages the powdered medication in the lower portion of nebulizer receptacle 450, which is of progressively decreasing transverse cross-section. As a result, there is achieved a high extent of solids entrainment in the gas stream, as discharged into inhalation pathway 426' via exit 421.

Best Mode For Carrying Out the Invention

In a preferred aspect for delivering nebulized liquid medicament to a patient in accordance with the present invention, the nebulizer system is suitably of a configuration as shown and described with reference to Figure 2 herein, as arranged for continuous delivery of liquid from a reservoir which is separate and distinct from the nebulizer device, being coupled thereto by suitable tubing or connection means including an interposed pump, to ensure continuous liquid delivery, and maintenance of a constant liquid level in the housing of the nebulizer device. In such system, the nebulizer features a jet passage member, e.g., of a type as shown in Figures 3 or 4 hereof, in which the nozzle orifice has an

equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch, and most preferably from about 0.010 inch to about 0.012 inch.

In a preferred arrangement for delivery of solid medicament, the nebulizer system may be arranged as shown in Figure 5, utilizing a nebulizer as described in connection with Figure 6 hereof.

In both liquid medicament and solid medicament delivery aspects, the flow of carrier gas through the jet passage member of the nebulizer is at a flow rate in the range of from about 0.5 to about 3.25 liters per minute, preferably from about 1.0 to about 3.0 liters per minute, and most preferably in the range of from about 2.2 to about 2.8 liters per minute.

Industrial Applicability

The nebulization technology of the present invention permits a low flow rate of carrier gas to be utilized in the delivery of medicament to a patient, without the deterioration of nebulization efficiency which has characterized prior art nebulization systems attempting to use flow rates below the conventional flow rate range of from about 6 to about 8 liters per minute.

The nebulization system of the present invention thus is highly efficacious in delivering medicaments to a pulmonary situs, including medicament species such as lung surfactants or precursors thereof, terbutaline, salbutamol, dexamethasone, chromolyn sodium, pentamidine, and bioactive substances encapsulated in a pulmonarily degradable medium.

THE CLAIMS

WHAT IS CLAIMED IS:

1. A nebulizer device, comprising:

- (a) a housing defining an interior volume therewithin, including a reservoir portion for holding medicament therein for entrainment into a carrier gas to form a delivery gas mixture comprising nebulized medicament and carrier gas;
- (b) a discharge port connected to the housing in flow communication with the interior volume therewithin, for discharging the delivery gas mixture from the housing;

(c) a jet passage member having (i) an inlet portion for introduction of carrier gas thereinto and (ii) a nozzle portion positioned in the interior volume of the housing for discharging carrier gas in jet form in the interior volume, for entrainment of medicament from the reservoir portion of the housing in the carrier gas jet, said nozzle portion comprising a nozzle orifice accommodating carrier gas flow therethrough, wherein the nozzle orifice has an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch.

2. A device according to claim 1, wherein the equivalent orifice diameter is in the range of from about 0.007 inch to about 0.018 inch.

3. A device according to claim 1, wherein the equivalent orifice diameter is in the range of from about 0.008 inch to about 0.015 inch.

4. A device according to claim 1, wherein the equivalent orifice diameter is in the range of from about 0.010 inch to about 0.012 inch.

5. A device according to claim 1, further comprising a nebulization structure mounted in the interior volume of the housing, including: an expansion chamber in flow-receiving communication with the nozzle portion of the jet passage member, said expansion chamber having an orifice therein, in alignment with the orifice of the jet passage member; an impingement baffle presenting an impingement surface in alignment with the orifices of the jet passage member and the

expansion chamber; and means for aspiratingly delivering liquid from the reservoir portion of the housing when liquid is contained in the reservoir and carrier gas is flowed in sequence through the orifices of the jet passage member and the expansion chamber at sufficient volumetric flow rate.

6. A device according to claim 5, wherein the orifice in the expansion chamber has an equivalent orifice diameter in the range of from about 0.025 inch to about 0.060 inch.

7. A device according to claim 5, wherein the orifice in the expansion chamber has an equivalent orifice diameter in the range of from about 0.030 inch to about 0.050 inch.

8. A device according to claim 1, further comprising pressurized carrier gas supply means coupled in gas-supplying relationship with the inlet portion of the jet passage member.

9. A device according to claim 1, further comprising a breathing circuit coupled with the discharge port for receiving delivery gas mixture and conveying same to a patient interconnected with the breathing circuit.

10. A device according to claim 1, further comprising means disposed in the interior volume of the housing for delivering liquid from the reservoir portion of the housing to a discharge locus of the nozzle orifice of the jet passage member, whereby delivered liquid is entrained in carrier gas flowed through the jet passage member when the reservoir portion contains liquid.

11. A method of delivering a nebulized medicant to a patient, comprising:

(a) providing a nebulizer apparatus including a breathing circuit coupled to the patient and including a nebulizer device (i) containing the medicant, and (ii) constructed and arranged for producing a pulmonarily effective nebulized medicant in a carrier gas passed through the nebulizer device at a carrier gas flow rate in the range of from about 0.5 to about 3.25 liters per minute;

(b) flowing the carrier gas through the nebulizer device at a flow rate in the range of from about 0.5 to about 3.25 liters per minute, to disperse the medicant into the carrier gas and form said pulmonarily effective nebulized medicant in the carrier gas, as a medicant/carrier gas mixture; and

(c) passing the medicant/carrier gas mixture through the breathing circuit to a pulmonary situs of the patient.

12. A method according to claim 11, wherein the carrier gas flow rate is in the range of from about 1.0 to about 3.0 liters per minute.

13. A method according to claim 11, wherein the carrier gas flow rate is in the range of from about 2.2 to about 2.8 liters per minute.

14. A method according to claim 11, wherein the medicant comprises a material selected from the group consisting of lung surfactants or precursors thereof, terbutaline, salbutamol, dexamethasone, chromolyn sodium, pentamidine, and bioactive substances encapsulated in a pulmonarily degradable encapsulant medium.

15. A method of delivering a nebulized medicant to a patient, comprising:

(i) providing a nebulizer apparatus including a breathing circuit coupled to the patient and including a nebulizer device, wherein the nebulizer device comprises:

(a) a housing defining an interior volume therewithin, including a reservoir portion for holding medicament therein for entrainment into a carrier gas to form a delivery gas mixture comprising nebulized medicament and carrier gas;

(b) a discharge port connected to the housing in flow communication with the interior volume therewithin, for discharging the delivery gas mixture from the housing;

(c) a jet passage member having (i) an inlet portion for introduction of carrier gas thereinto and (ii) a nozzle portion positioned in the interior volume of

the housing for discharging carrier gas in jet form in the interior volume, for entrainment of medicament from the reservoir portion of the housing in the carrier gas jet, said nozzle portion comprising a nozzle orifice accommodating carrier gas flow therethrough, wherein the nozzle orifice has an equivalent orifice diameter in the range of from about 0.005 inch to about 0.020 inch;

(II) disposing a medicant in the reservoir portion of the housing;

(b) flowing the carrier gas through the jet passage member of the jet nebulizer device at a flow rate in the range of from about 0.5 to about 3.25 liters per minute, to disperse the medicant into the carrier gas and form a pulmonarily effective nebulized medicant in the carrier gas, as a medicant/carrier gas mixture; and

(c) passing the medicant/carrier gas mixture through the breathing circuit to a pulmonary situs of the patient.

16. A method according to claim 15, wherein the carrier gas flow rate is in the range of from about 1.0 to about 3.0 liters per minute.


17. A method according to claim 15, wherein the carrier gas flow rate is in the range of from about 2.2 to about 2.8 liters per minute.

18. A method according to claim 15, wherein the medicant comprises a material selected from the group consisting of lung surfactants or precursors thereof, terbutaline, salbutamol, dexamethasone, chromolyn sodium, pentamidine, and bioactive substances encapsulated in a pulmonarily degradable encapsulant medium.

19. A method according to claim 15, wherein the medicant comprises a material selected from the group consisting of lung surfactant and pentamidine.

20. A device according to claim 15, wherein the equivalent orifice diameter is in the range of from about 0.007 inch to about 0.018 inch.

1/6



2/6






Fig. 2

3/6



4/6

**FIG. 4****SUBSTITUTE SHEET**

5/6





FIG. 5

6/6

**FIG. 6**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/07515

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :Please See Extra Sheet.
US CL :128/200.18, 200.21, 203.12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/200.14, 200.18, 200.19, 200.21, 203.12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, search terms: nebuliz?, jet or nozzle, orifice, orifice diameter, inch#, 128/clas, cm or mm or centimeter# or millimeter#.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/Y	US, A, 5,086,765 (LEVINE) 11 FEB 1992. SEE THE ENTIRE DOCUMENT.	1, 5, 8-10/ 2-4, 6, 7, & 14- 20
X/Y	US, A, 4,054,622 (LESTER) 18 OCT 1977. SEE THE ENTIRE DOCUMENT.	11 & 12/ 2-4, 6, 7, & 13- 20
Y	US, A, 4,344,574 (MEDDINGS ET AL) 17 AUG 1982. SEE THE ENTIRE DOCUMENT.	20

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
* Special categories of cited documents:		*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance		*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date		*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		*&*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means			
P document published prior to the international filing date but later than the priority date claimed			

Date of the actual completion of the international search	Date of mailing of the international search report
21 September 1993	28 SEP 1993,

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer KIMBERLY L. ASHER Telephone No. (703) 308 - 0858
Facsimile No. NOT APPLICABLE	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/07515

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (5):

A61M 11/00, 15/00, 16/10; B05B 1/26